Seres therapeutics and nestlÉ health science present late-breaking data on vowst™, a microbiota-based oral therapeutic for prevention of recurrence of c. difficile infection in adults, at asm microbe 2023

Cambridge, mass. & hoboken, n.j.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) and nestlÉ health science today announced the presentation of a post-hoc analysis from the phase 3 development program for vowst™ (fecal microbiota spores, live-brpk), the first and only u.s. food and drug administration (fda)-approved orally administered microbiota-based therapeutic to prevent recurrence of c. difficile infection (cdi) in adults following antibacterial treatment for recurrent cdi (rcdi).
MCRB Ratings Summary
MCRB Quant Ranking